8:45-9:10

The Global Funds’ Lessons Learned Regarding ARV

Drug Scale-up in Resource-Constrained Settings

Dr. Bernhard Schwartlander

Director

Strategic Information and Measurement

Global Fund to Fight AIDS, TB, and Malaria

Geneva, Switzerland

9:10-9:35

The U.S. Emergency Plan for Antiretroviral Scale-up:

The Latest Programmatic Developments

Dr. Joe O’Neil

Deputy Coordinator

Office of the Global AIDS Coordinator

Department of State

Washington, DC

9:35-9:55

General Discussion

9:55-10:15

BREAK

Antecedents

10:15-10:40

Durability of ARV Therapy: U.S. Experience and Its Implications for Resource-Constrained Settings

Dr. Robert Redfield

Cofounder and Director of Clinical Care and Research Division, Institute of Human Virology

University of Maryland

Baltimore, MD

10:40-11:05

A U.S. Clinical Perspective on the Implications of ARV

Resistance for Resource-Constrained Settings

Dr. Steven Deeks

Associate Clinical Professor of Clinical Medicine

University of California, San Francisco

San Francisco, CA

11:05-11:30

Lessons Learned from the Scale-up of ARV Treatment in Brazil

Dr. Mauro Schechter

Professor of Infectious Diseases

Universidade Federal do Rio de Janeiro, Brazil



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement